Lopez James, Yarlagadda Naveen, Gheith Zaid, Mohan Meera, Sasapu Appalanaidu
Department of Hematology/Oncology, University of Arkansas for Medical SciencesLittle RockArkansas.
Proc (Bayl Univ Med Cent). 2019 Oct 25;33(1):59-61. doi: 10.1080/08998280.2019.1668719. eCollection 2020 Jan.
Nivolumab, a monoclonal antibody against programmed cell death-1 used to treat multiple cancers, has fewer side effects than traditional chemotherapy but has displayed a propensity to cause a host of immune-related adverse events. We describe a case of nivolumab immune-mediated neurotoxicity in a 42-year-old Hispanic man with relapsed Hodgkin lymphoma who presented with unilateral facial droop, dysarthria, and dysphagia 1 week after receiving nivolumab. His symptoms rapidly improved with steroids, intravenous immunoglobulin, and infliximab.
纳武单抗是一种用于治疗多种癌症的抗程序性细胞死亡蛋白1单克隆抗体，与传统化疗相比副作用较少，但已显示出易引发一系列免疫相关不良事件的倾向。我们描述了一例42岁西班牙裔复发性霍奇金淋巴瘤男性患者出现纳武单抗免疫介导的神经毒性的病例，该患者在接受纳武单抗治疗1周后出现单侧面部下垂、构音障碍和吞咽困难。他的症状通过使用类固醇、静脉注射免疫球蛋白和英夫利昔单抗后迅速改善。
